Reaction
Terminal Ileitis reporting signals
As of the last recalculation, Terminal Ileitis appears in 595 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-FKJP (PRR 109.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Fkjp | 117 | 109.7 | 110.0 |
| Adalimumab-Aaty | 117 | 107.4 | 107.7 |
| Adalimumab-Adaz | 122 | 101.5 | 101.7 |
| Vedolizumab | 97 | 46.9 | 46.9 |
| Azathioprine | 94 | 44.1 | 44.2 |
| Cholestyramine | 14 | 41.5 | 41.5 |
| Mesalamine | 52 | 35.4 | 35.4 |
| Thiotepa | 9 | 33.5 | 33.5 |
| Phytonadione | 8 | 33.4 | 33.5 |
| Calcium Gluconate | 11 | 32.5 | 32.5 |
| Ustekinumab | 80 | 31.4 | 31.5 |
| Magnesium Sulfate In Water For | 11 | 30.7 | 30.7 |
| Magnesium Sulfate Heptahydrate | 11 | 30.1 | 30.1 |
| Magnesium Sulfate | 11 | 30.0 | 30.0 |
| Clobetasol Propionate Ointment Usp, 0.05% | 8 | 27.5 | 27.6 |
| Clobetasol Propionate | 8 | 27.4 | 27.4 |
| Infliximab-Dyyb | 22 | 27.3 | 27.3 |
| Capecitabine | 61 | 25.9 | 25.9 |
| Mercaptopurine | 12 | 24.7 | 24.7 |
| Valganciclovir | 13 | 24.6 | 24.7 |
| Valganciclovir Hydrochloride | 13 | 24.6 | 24.7 |
| Risankizumab-Rzaa | 29 | 13.0 | 13.0 |
| Atezolizumab | 14 | 12.9 | 12.9 |